Previous 10 | Next 10 |
2023-12-17 08:45:00 ET Building a better proverbial mousetrap isn't always a necessary condition for the success of a business, but doing so can help. Those corporations that break new ground often end up being handsomely rewarded, as are those investors bold enough to hold shares of these ...
2023-12-16 09:45:00 ET On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light to commercialize their gene therapy for sickle cell dis...
2023-12-16 06:55:00 ET You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the S&P 500 often rises noticeably in the final five trading days...
2023-12-16 05:53:00 ET It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP) . The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX) , won U.S. regulatory approval for Casgevy (exa-cel) in treating sickle cell disease (SCD) on Dec. 8, 2023. ...
2023-12-15 11:56:19 ET More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc. Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr T...
2023-12-15 05:30:00 ET CRISPR Therapeutics (NASDAQ: CRSP) scored a major win in recent days, earning the world's first regulatory nod for a CRISPR-based gene-editing treatment. The U.S. Food and Drug Administration (FDA) approved Casgevy (developed as exa-cel) for sickle cell diseas...
2023-12-13 09:47:07 ET Verizon Communications Inc (VZ) VZ is trading DOWN for the last 4 days, and it at trading at $36.83 with volume of 4,933,910 and a one day change of $-0.47 (-1.26%). Verizon Communications Inc has a 52-week low of 30.74 and a 52-week high of $42.58. The busine...
2023-12-13 09:33:01 ET More on Editas, Vertex, etc. Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript) Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed Editas Medicine, Inc. (EDIT)...
2023-12-12 06:00:00 ET Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes responsible for disease. But CRISPR Therapeutics is farther...
2023-12-11 12:41:31 ET On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it. Just three days ago, CRISPR announced that the U.S. Food and Drug...
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website:
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...